Valitacell and Solentim to collaborate on candidate detection

21 February 2019
research_technology_lab_big

Irish cell-based manufacturing firm Valitacell has teamed up with the UK’s Solentim on a project aimed at enabling earlier identification of biological candidates.

Solentim, a Bournemouth-based firm which produces cell line development instruments, will work with Valitacell to try to accelerate the development of breakthrough medicines.

The collaboration will leverage Valitacell’s in-line analytical profiling technologies and data driven/machine learning approach, together with Solentim’s image-driven liquid handling and cell measurement technology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology